AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints in the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD).
The Kronos trial was a 24-week, double blind trial to determine the efficacy of PT010 in patients who were given two doses each day.
The full data was not revealed but instead a list of primary endpoints was offered and the conclusions of which were met:
